The following links are provided by IPC for the benefit of its users and members. IPC does not attest to the accuracy of or assume any responsibility for the content or information provided by linked sites, nor does it endorse or recommend any specific content or information contained therein. Please be aware that when you exit the IPC website you are subject to the policies and procedures of the new site.
North American
In the latest Psoriasis Review IPC's bi-annual review of the latest news in the field of psoriasis. read the latest issue
Psoriasis News Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis3/31/2020 10:15:00 AMLilly's TALTZ® (IXEKIZUMAB) receives U.S. FDA approval for the treatment of pediatric patients with moderate to severe plaque psoriasis Statement on the Coronavirus (COVID-19) Outbreak3/11/2020 1:09:00 PMFor psoriasis patients diagnosed with COVID-19 disease, the IPC recommends physicians discontinue or postpone use of immunosuppressant medications. This is in accordance with established psoriasis treatment guidelines, which state immunosuppressive psoriasis treatments are contraindicated in patients with active infections. NOW AVAILABLE: IPC's January 2020 Psoriasis Review newsletter2/6/2020 10:54:00 AMJust published - IPC's latest issue of the Psoriasis Review newsletter is now available! This issue features the Top Five Papers in psoriasis research, symposia reports, IPC news, and more! IPC Think Tank 20192/6/2020 More News